These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 27715341

  • 1. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
    Tramutola A, Arena A, Cini C, Butterfield DA, Barone E.
    Expert Rev Neurother; 2017 Jan; 17(1):59-75. PubMed ID: 27715341
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 5. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 9. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.
    Bae CS, Song J.
    Int J Mol Sci; 2017 Nov 22; 18(11):. PubMed ID: 29165354
    [Abstract] [Full Text] [Related]

  • 10. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?
    Hölscher C, Li L.
    Neurobiol Aging; 2010 Sep 22; 31(9):1495-502. PubMed ID: 18930564
    [Abstract] [Full Text] [Related]

  • 11. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease.
    Yildirim Simsir I, Soyaltin UE, Cetinkalp S.
    Diabetes Metab Syndr; 2018 May 22; 12(3):469-475. PubMed ID: 29598932
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D, Foltynie T.
    Drug Discov Today; 2016 May 22; 21(5):802-18. PubMed ID: 26851597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
    Hölscher C.
    J Endocrinol; 2014 Apr 22; 221(1):T31-41. PubMed ID: 23999914
    [Abstract] [Full Text] [Related]

  • 17. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.
    Talbot K, Wang HY.
    Alzheimers Dement; 2014 Feb 22; 10(1 Suppl):S12-25. PubMed ID: 24529520
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?
    de la Monte SM.
    J Alzheimers Dis; 2024 Feb 22; 101(s1):S317-S343. PubMed ID: 39422949
    [Abstract] [Full Text] [Related]

  • 20. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Biochem Soc Trans; 2014 Apr 22; 42(2):593-9. PubMed ID: 24646283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.